ESMO 2024 | Subset analysis of pembrolizumab efficacy in the AMBASSADOR study
Andrea Apolo, MD, National Cancer Institute, Bethesda, MD, examines subset analyses in the AMBASSADOR study (NCT03244384), which assessed adjuvant pembrolizumab in urothelial cancer. PD-L1 positive patients (combined positive score ≥10) had superior disease-free survival (DFS) compared to PD-L1 negative patients, though both groups benefited from pembrolizumab. Lymph node status also impacted prognosis, with worse outcomes for higher nodal involvement (N2, N3). Recurrence patterns by metastatic sites, including lymph nodes, lungs, liver, and bones, showed slight distribution differences based on treatment, offering hypothesis-generating insights. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
